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Background: The interval cancer rate is an important pa-
rameter for determining the sensitivity of a screening pro-
cedure and the screening interval. We evaluated the time
and mechanism of detection and the stage distribution of
interval prostate cancers diagnosed during a 4-year screen-
ing interval. Methods: We determined the rate of interval
cancers and the sensitivity of the screening protocol (involv-
ing prostate-specific antigen, digital rectal and transrectal
ultrasound examinations) in a cohort of 17 226 men (8350 on
the screened arm, 8876 on the control arm) enrolled consec-
utively on the European Randomized Study of Screening for
Prostate Cancer–Rotterdam. Men on the screened arm re-
ceived a first screen between October 1993 and December
1996 and a scheduled second screen 4 years later. Prostate
cancers detected in men enrolled on the control arm over the
same 4-year period and, between screens, in men on the
screened arm, were identified by linkage to the Dutch na-
tional cancer registry. Results: During the first screen, 412
prostate cancers were detected. During the subsequent
4-year period, 135 cancers were diagnosed in men in the
control arm and 25 cancers were diagnosed in men in the
screened arm. Seven of the 25 cancers were diagnosed in
men who had refused a recommended biopsy at their initial
screen. Of the remaining 18 cancers, all were classified as
stage T1A–C or T2A and none were poorly differentiated or
metastatic. The rate of interval cancers relative to the num-
ber of cancers in the control group was 18.5% (25/135), or
13.3% (18/135), if the seven who refused an initial biopsy
were excluded. The sensitivity of the screening protocol was
79.8% when considering all 25 interval cancers and 85.5%
when considering 18 interval cancers. Conclusion: The in-
terval cancer rate with a 4-year screening interval was low,
confirming that the screening procedure has a high sensitiv-
ity and that the 4-year screening interval is reasonable.
[J Natl Cancer Inst 2003;95:1462–6]
The quality and effectiveness of a cancer screening program
cannot be evaluated on the basis of results from the initial
screening round. Instead, these properties must be evaluated
with consideration for crucial indicators, such as detection rates
from subsequent screening rounds, interval cancer rates, under-
lying cancer incidence, and tumor characteristics.
It will be several years before the outcomes, including effects
on cancer-related mortality, of population-based, randomized
screening trials—such as the European Randomized Study of
Screening for Prostate Cancer (ERSPC) (1) and the Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
(2)—will be available. In the meantime, intermediate endpoint
analyses are important indicators for the quality of the screening
procedures. One such intermediate endpoint for prostate cancer
screening is the rate of interval cancers, i.e., cancers detected in
the screened population between screening rounds and outside
screening trials. Because the rate of interval cancers reflects the
number of and the time needed for new cancers to surface clini-
cally, it is an important parameter for determining the sensitivity
of the screening procedure and the proper screening interval.
The sensitivity of the screening procedure in the ERSPC, which
included collection of sextant biopsy specimens, was estimated
to be approximately 70% (3,4). In this study, we evaluated the
time and mechanism of detection and the stage distribution of
prostate cancers diagnosed during a 4-year screening interval in
a subgroup of the ERSPC study population.
PATIENTS AND METHODS
Patients
We studied a cohort of 17 226 men aged 55–74 years (8350
men in the intervention arm and 8876 men in the control arm)
(Fig. 1) enrolled on the ERSPC–Rotterdam. All men in the in-
tervention arm had their first screen between October 1993 and
December 1996. ERSPC–Rotterdam uses a 4-year screening
interval. The second screen was completed by the end of De-
cember 2000. This allowed a full 4-year period for the study
of interval cancers. All men in the control arm were enrolled
simultaneously.
At the first screen, all participants in the intervention arm
were offered a prostate-specific antigen (PSA) level measure-
ment, digital rectal examination (DRE), and transrectal ultra-
sound (TRUS) examination. Individuals who had PSA levels
equal to or higher than 4.0 ng/mL or who had PSA levels of
0–3.9 ng/mL and suspicious DRE and/or TRUS results were
then recommended to have lateral sextant transrectal biopsies, as
stated for the Rotterdam screening regimen. All participants re-
ceived extensive information about potential benefits and harms
of screening for prostate cancer as part of the informed consent
procedure.
To identify individuals with prostate cancer in each study
arm, including interval carcinomas in individuals in the inter-
vention arm, a database from the local Rotterdam Comprehen-
sive Cancer Registry was checked annually. For men diagnosed
with prostate cancer and those known to have died from other
causes, data regarding the diagnosis of prostate cancer were
collected and entered into the ERSPC database. All data regard-
ing prostate cancer staging and management were obtained by
reviewing the patients’ medical records at the regional hospitals.
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For individuals identified with interval carcinomas, histologic
slides of sections of prostate cancer biopsy specimens were re-
trieved from the pathologic storage facilities of the local hospi-
tals. All diagnoses and Gleason scores abstracted from the pa-
tients’ medical records were reviewed by one of the authors
(T. H. van der Kwast). If discrepancies occurred among the di-
agnoses and Gleason scores from the patients’ medical records
and those assigned after review, blinded re-grading by the ref-
erence pathologies was used. The pathologic features of the
cancers, including the extent of the cancers and Gleason scores,
in men who had undergone radical prostatectomy were obtained
in the same way as those of the biopsy specimens to collect a
maximum amount of reliable prognostic information. All tumors
were staged according to the 1992 Tumor–Node–Metastasis
(TNM) System (5). All men diagnosed with prostate cancer,
regardless of study arm, received standard medical care, which
meant that the evaluation of symptoms and diagnosis and
management of the prostate cancer were provided by local
urologists not associated with the study. The study was approved
by the Minister of Health of The Netherlands (via letters dated
15 August 1997 and 05 February 2001 from Dr. E. Borst-Eilers,
The Hague). Written informed consent was obtained from each
participant.
Statistical Analysis
The rate of interval cancers was calculated as the ratio of the
number of interval cancers to the number of cancers found in the
control group during the same time period. Sensitivity was cal-
culated according to the proportional incidence method (6).
RESULTS
The ERSPC–Rotterdam recruited 42 376 participants and ran-
domly assigned them to either the intervention arm (21 210 men)
or the control arm (21 166 men) (Fig. 1). For the purpose of this
study, we used a cohort of 17 226 men (8350 in the intervention
arm and 8876 in the control arm) who were consecutively en-
rolled on the ERSPC–Rotterdam. Men in the intervention arm
had their first screen between October 1993 and December 1996.
At the end of December 2000, all participants in the intervention
arm had been followed to the completion of their scheduled
second screen, a 4-year follow-up period.
Of the 152 prostate cancers diagnosed among individuals in
the control arm, 135 were diagnosed within 4 years of random-
ization. Among individuals in the intervention arm, 25 prostate
cancers were not diagnosed as a result of screening but were
diagnosed outside the trial and within 4 years of randomization.
The prognostic characteristics of the 25 cancers are described in
Tables 1–4. Twenty-two of the 25 cancers were classified as
early-stage (T1A, T1B, T1C, or T2A). None of the cancers were
poorly differentiated or metastatic (N+ or M+).
Of the 25 cancers, seven were diagnosed among men who
had a biopsy indication initially but who refused a recommended
biopsy at the initial screen. Three of the seven cancers were
advanced cancers, with a T3 or worse tumor stage. None of these
seven men had metastatic disease. Five of the seven cancers
were detected within 1 year of the initial screening examination
(Table 1).
Of the remaining 18 men diagnosed with an interval prostate
cancer, four were aged 75 years or older. In three of the four
men, the cancers were carcinomas diagnosed by transurethral
Fig. 1. ERSPC–Rotterdam consort diagram relating to interval cancers.
Table 1. Tumor characteristics of interval cancers among men enrolled in the European Randomized Study of Screening for Prostate
Cancer–Rotterdam who refused a recommended biopsy at the initial screen and their therapy choices (n  7)*
Initial screen Diagnosis and treatment
Patient
PSA,
ng/mL DRE TRUS Biopsy
Interval,
mo† Age, y
PSA,
ng/mL T stage‡
Gleason score for
biopsy specimen Therapy
pT
stage‡
Gleason score for
RP tissue specimen
1 6.6 B B N 44 62 8.8 T1C 6 Radical prostatectomy PT2C 5
2 7.1 B B N 25 67 9.6 T1C 6 Radiotherapy — —
3 16.0 — — N 8 73 18.7 T1C 8 Radiotherapy — —
4 21.0 — — N 0 61 21.0 T1C 7 Radical prostatectomy PT2A 6
5 62 T2C T2C N 5 71 65.0 T3A 9 Radiotherapy — —
6 2.8 T2C B N 3 68 2.8 T3B 6 Radiotherapy — —
7 19.1 — — N 4 72 19.1 T4 7 Endocrine therapy — —
*PSA  prostate-specific antigen; DRE  digital rectal examination; TRUS  transrectal ultrasound examination; RP  radical prostatectomy; B  benign;
N  not done (refused).
†Interval refers to the number of months between the first screen and a prostate cancer diagnosis.
‡T stage and pT stage represent tumor extent determined before and after excision of the prostate. All tumors were staged according to the Tumor–Node–
Metastasis System of 1992 (5). No lymph nodal or distant metastases were found.
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resection of the prostate (TURP), which was done for what was
thought to be benign disease. These three cancers are considered
incidental cancers (Table 2). The remaining 14 cancers were
diagnosed clinically, as indicated in Tables 3 and 4. Five of the
cancers were diagnosed by cystoprostatectomy for bladder can-
cer, and two were diagnosed by TURP for benign disease. The
other seven cancers were diagnosed because of increasing PSA
levels or complaints of prostatism.
During the initial screen, 412 prostate cancers were diag-
nosed. Thus, the proportion of interval cancers among all can-
cers diagnosed in men in the screening arm was 6.1% (25/412).
The proportion of interval cancers in men in the screened arm,
relative to cancers diagnosed in men in the control arm during
the 4-year period after randomization was 18.5% (25/135). If
the seven men who refused a biopsy after their initial screen are
not included among the interval cancers, then the proportion of
interval cancers relative to the control arm would be 13.3%
(18/135). Other definitions of interval cancer rates can easily be
applied using the information provided in the tables.
The incidence of prostate cancer was 21 per 1000 person-
years among men in the screened arm and 3.9 per 1000 person-
years among men in the control arm. The number of screen-
negative men in our cohort is 7938, which represents men who
actually had a negative screen (7798), men from whom a biopsy
specimen could not be taken because they used anticoagulants
(48), and men who were non-attenders (92). The expected num-
ber of cancers in the screen-negative men would be 123.8 (7938
× 3.9/1000 × 4 years of follow-up). Sensitivity was calculated
according to the proportional incidence method (6) and was
estimated to be 79.8% (123.8 – 25/123.8). If the seven men who
refused a biopsy during the first screen were not considered
among the interval cancers, then the sensitivity was estimated to
be 85.5%.
DISCUSSION
This is the first report on interval carcinomas in prostate
cancer screening from the ERSPC. The rate of interval cancers
was low and reflects the usefulness of a screening interval of
at least 4 years. In general, cancers not detected in the initial
screening visit may be detected as interval cancers, may be
detected in the second screening round, or may remain occult
during the lifetime of their carriers. The occurrence of interval
carcinomas may be the result of a lack of sensitivity of the
screening test or of an interscreening interval that is too long.
Increased sensitivity (and a lower proportion of interval cancers)
can be reached with more aggressive screening strategies, but
such an approach would increase the rate of overdiagnosis, a
problem that is inherent in screening for prostate cancer.
Characterization of Interval Cancers
In our study, interval cancers were defined as prostate cancers
detected during 4 years after randomization in the screened
population but outside the screening protocol. Because the first
screening round is complete only if men who are recommended
to have a biopsy did in fact do so, the cancers found in the seven
patients listed in Table 1 who refused to have a prostate biopsy
may not represent true interval cancers. The information regard-
ing classification of the interval cancers in the tables is purely
descriptive and does not contain any judgments on what may be
a clinically relevant or irrelevant cancer. Some cancers are di-
agnosed as so-called “incidental prostate cancers” (i.e., T1A and
T1B cancers). Their high prevalence of approximately 30% at
autopsy is well established in men aged 50–60 years (7). Some
incidental prostate cancers were found during treatment for other
diseases, such as during cystoprostatectomy for bladder cancer
(cases 12–16) and during transurethral resection for obstructive
benign prostatic hyperplasia (cases 17 and 18). Four cases (11,
19, 20, and 21), all stage T1C, were found through opportunistic
screening. By definition, a T1C cancer can be diagnosed only on
the basis of an elevated PSA level.
Potential Biases
It is unclear why interval cancers are rarely mentioned in the
prostate cancer screening literature. One reason may be that
interval cancers do not occur because of the short intervals that
are in general use (6–12 months) and are recommended in the
United States (8). ERSPC chose a 4-year screening interval in
light of the limited evidence available regarding lead time in
prostate cancer (9–11) during the ERSPC protocol development
phase (1992 through 1994). The Swedish center of ERSPC uses
a screening interval of 2 years and has described nine interval
cancers that were found over a 4-year period (12). Their data
cannot be compared with ours because the difference in screen-
ing intervals will bias the determination of rates of interval
cancers.
Several factors could have influenced the results of this study
by either raising or lowering the number of interval cancers or
their rate relative to prostate cancer incidence in the control
group. These factors include the frequency of screening, the
screening procedures used, the age group screened, and the un-
Table 2. Tumor characteristics of interval cancers detected among men enrolled in the European Randomized Study of Screening for
Prostate Cancer–Rotterdam who were not eligible for rescreening because of age (older than 75 years) and their therapy choices (n  4)*
Initial screen Diagnosis and treatment
Patient
PSA,
ng/mL DRE TRUS
Biopsy
(histology)
Interval,
mo† Age, y
PSA,
ng/mL T stage‡
TURP/Gleason score
for biopsy specimen Therapy
8 1.4 B B N 44 76 1.0 T1A Watchful waiting
9 2.8 B T2 Y (chronic prostatitis) 46 78 3.2 T1B 4 Watchful waiting
10 4.0 B B Y (no malignancy) 33 76 6.0 T1B 4 Watchful waiting
11 2.4 B B N 48 77 5.3 T1C 6 Radiotherapy
*PSA  prostate-specific antigen; DRE  digital rectal examination; TRUS  transrectal ultrasound examination; TURP  transurethral resection of the
prostate (for apparently benign disease); B  benign; N  not done; Y  yes, biopsy performed.
†Interval refers to the number of months between the first screen and a prostate cancer diagnosis.
‡T stage  tumor extent determined before and after excision of the prostate. All tumors were staged to the Tumor–Node–Metastasis System of 1992 (5).
No lymph nodal or distant metastases were found.
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derlying incidence. It is well known that collecting more biopsy
specimens will detect more cancer (13–15). This knowledge has
led to a change in clinical practice in several ERSPC countries
but not in The Netherlands. However, 49 cancers were detected
at temporary early rescreens performed on men in ERSPC–
Rotterdam who had a negative biopsy during the first screening
round (16). These cancers are part of the first round detection
rate and therefore are likely to have decreased the number of
interval cancers.
The prevalence of opportunistic screening, defined as screen-
ing of participants outside the study, in the intervention and the
control arms could be another important source of bias. Oppor-
tunistic screening was therefore subject to continuous monitor-
ing. The preliminary results of opportunistic screening in the
ERSPC have been published (17,18). The data show that effec-
tive screening, which involved a PSA test combined with a
biopsy according to indication, occurred in about 10% of men in
the control arm over a 4-year period (18). The proportion of men
who were classified as T1C and, by definition, were diagnosed
by PSA-driven screening is presently under investigation.
Our results could also be biased by incomplete incidence data
obtained from the cancer registry. However, all Dutch cancer
registries are maintained according to one countrywide protocol;
one regional comprehensive cancer center that follows the pro-
tocol evaluated the completeness of cancer registration and
found that 96.2% of the eligible malignancies were included in
the registry (19). Thus, it is reasonable to expect that the com-
pleteness of the data obtained from the Rotterdam Cancer Reg-
istry is similar. ERSPC procedures include a double check of the
incidence data obtained from the registry. This additional check
has rarely led to corrections of the cancer registry database.
Lead Time
Lead time is an important codeterminant of the sensitivity of
a screening procedure. Determinations of lead time (9–11) were
made on the basis of clinical diagnoses of prostate cancer asso-
ciated with archived serum samples used during follow-up pe-
riods of 10–15 years. Gann et al. (11) point out that lead time is
not a parameter that depends exclusively on test characteristics
but a parameter that depends also on prognostic factors such as
stage at the time of diagnosis, tumor aggressiveness, patient age,
and other disease-related factors. Factors associated with a
worse outcome are likely to be associated with a shorter lead
time than those associated with clinical cancers. The ERSPC has
made two attempts to model lead time. Auvinen et al. (20)
estimated a lead time of 5–7 years on the basis of the duration of
Table 3. Tumor characteristics of interval cancers detected among men enrolled in the European Randomized Study of Screening for
Prostate Cancer–Rotterdam who were diagnosed with cancer by cystoprostatectomy or transurethral resection of the prostate (TURP; for
apparently benign disease) and their therapy choices (n  7)*
Initial screen Diagnosis and treatment
Patient
PSA,
ng/mL DRE TRUS
Biopsy
(histology)
Interval,
mo† Age, y
PSA,
ng/mL T stage‡ Therapy pT stage‡
RCP/TURP
Gleason score
12 1.6 B B N 43 74 — — Cystoprostatectomy PT2C 7
13 1.7 B B N 38 73 2.4 — Cystoprostatectomy PT2A 4
14 1.8 B B N 10 65 2.4 — Cystoprostatectomy PT3A 5
15 1.8 B B N 32 70 2.5 — Cystoprostatectomy PT2A 6
16 7.2 B B Y (hyperplasia) 10 71 8.0 — Cystoprostatectomy PTX 6
17 2.2 T2A T2A Y (no malignancy) 4 67 3.1 T1A Watchful waiting — 5
18 4.9 B B Y (no malignancy) 28 68 6.0 T1B Watchful waiting — 3
*PSA  prostate-specific antigen; DRE  digital rectal examination; TRUS  transrectal ultrasound examination; RCP  radical cystoprostatectomy;
B  benign; N  not done; Y  yes, biopsy performed.
†Interval refers to the number of months between the first screen and a prostate cancer diagnosis.
‡T stage and pT stage  tumor extent determined before and after excision of the prostate. All tumors were staged according to the Tumor–Node–Metastasis
System of 1992 (5). No lymph nodal or distant metastases were found.
Table 4. Tumor characteristics of interval cancers detected among men enrolled in the European Randomized Study of Screening for
Prostate Cancer–Rotterdam who were clinically diagnosed with cancer and their therapy choices (n  7)*
Initial screen Diagnosis and treatment
Patient
PSA,
ng/mL DRE TRUS
Biopsy
(histology)
Interval,
mo†
Age,
y
PSA,
ng/mL
T
stage‡
Gleason score for
biopsy specimen Therapy
pT
stage‡
Gleason score for
RP tissue specimen
19 3.0 B B N 26 63 5.3 T1C 6 Watchful waiting
20 3.6 B B N 30 68 5.4 T1C 6 Watchful waiting
21 2.6 B B N 26 73 6.4 T1C 6 Radiotherapy
22 3.0 B B N 31 74 5.3 T2A 7 Radiotherapy
23 3.4 B B N 28 72 6.9 T2A 6 Radiotherapy
24 18.2 B B Y (prostatitis) 21 67 15.4 T2A 7 Radical prostatectomy PT3a 6
25 20.2 T2C T2A Y (no malignancy) 28 69 25.0 T2A 6 Radical prostatectomy pT2A 6
*PSA  prostate-specific antigen; DRE  digital rectal examination; TRUS  transrectal ultrasound examination; RP  radical prostatectomy; B  benign;
N  not done; Y  yes, biopsy performed.
†Interval refers to the number of months between the first screen and a prostate cancer diagnosis.
‡T stage and pT stage  tumor extent determined before and after excision of the prostate. All tumors were staged according to the Tumor–Node–Metastasis
System of 1992 (5). No lymph nodal or distant metastases were found.
Journal of the National Cancer Institute, Vol. 95, No. 19, October 1, 2003 ARTICLES 1465
follow-up that was needed to accrue the same expected number
of incident prostate cancer cases in the absence of screening as
were detected in the initial screening round. These estimates
vary from those found by Draisma et al. (21) who, using the
MISCAN technique, found that for a group of men aged 55–75
years and a screening interval of 4 years, lead time was 10.3
years (range 9.9–11.2 years). Lead times were age-dependent
(21). This information also confirms the choice of a long screen-
ing interval in the ERSPC.
Sensitivity of PSA-based screening was estimated by
Hakama et al. (22), who used follow-up and PSA determinations
from archived serum samples. They studied 21 387 men in
whom 104 prostate cancers were detected clinically. The sensi-
tivity of the PSA test was 86% for cancers that were diagnosed
within 5 years of collecting the blood sample. This estimate is in
line with our sensitivity results of 79.8%–85.5%. However, it
should be noted that we used PSA, DRE, and TRUS in our
screening protocol.
Clinical Importance of Interval Cancers
If we had detected a large number of interval cancers and/or
interval cancers with advanced stage or otherwise poor prognos-
tic factors, it would have indicated that the screening protocol
had a low sensitivity. However, all interval cancers were de-
tected at a locally confined stage, and only three had an unfa-
vorable Gleason score of 7, one in Table 3 and two in Table 4,
not counting those in Table 1 (these are the case patients who
refused biopsy). The preponderance of low Gleason scores is in
line with the fact that many of the cancers were detected by
transurethral resection for benign prostatic hyperplasia and as
incidental findings of cystoprostatectomy. T stage and Gleason
score have poor intra- and interobserver reproducibility and poor
correlation with definitive findings in radical prostatectomy
specimens and often result in understaging. Future screening
tests and screening intervals will have to consider these diffi-
culties and aim to identify aggressive cancers in time for curative
management.
CONCLUSION
The rate of interval cancers found within ERSPC–Rotterdam
with a 4-year screening period was exceedingly low. The inter-
val cancers were associated with favorable prognostic factors.
The data confirm a high sensitivity of the screening procedure
and the usefulness of a 4-year screening interval. The resulting
estimates of lead time are in agreement with the findings of
others (9–11,21) and with the long natural history of the disease.
The results confirm that very few, if any, aggressive prostate
cancers escape screening with the procedures used within the
ERSPC.
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